According to the results of a study presented at the 2007 San Antonio Breast Cancer Symposium, adjuvant chemotherapy with Taxotere® (docetaxel) and cylophosphamide results in better survival than adjuvant chemotherapy with doxorubicin and cyclophosphamide.
Adjuvant (post-surgery) plays an important role in the treatment of many patients with early breast cancer. In addition to identifying new chemotherapy drugs, researchers continue to explore new combinations of drugs.
To compare two different adjuvant chemotherapy regimens- Taxotere/cyclophosphamide (TC) and doxorubicin/cyclophosphamide (AC)-researchers conducted a clinical trial among 1,016 women with Stage I to Stage III breast cancer. Half the patients received four cycles of TC, and half received four cycles of AC. Women who were candidates for radiation therapy and/or hormonal therapy also received these treatments.
Study participants have now been followed for a median of seven years.
- Overall survival was 87% among patients treated with TC and 82% among patients treated with AC.
- Disease-free survival was 81% among patients treated with TC and 75% among patients treated with AC.
- TC also resulted in better disease-free survival in the subset of women age 65 or older.
At-home Genetic Testing may be Convenient, but it isn’t Complete
At-home genetics kits that reveal information about the risk of developing certain cancers may represent a risky step in our on-demand culture.
The researchers conclude that TC chemotherapy resulted in better disease-free and overall survival than AC chemotherapy.
Reference: Jones S, Holmes F, O’Shaughnessy J. Extended follow-up and analysis by age of the US Oncology Adjuvant trial 9735: docetaxel/cyclophosphamide is associated with an overall survival benefit compared to doxorubicin/cyclophosphamide and is well-tolerated in women 65 or older. Presented at the 30th Annual San Antonio Breast Cancer Symposium. San Antonio, TX, December 13-16, 2007. Abstract #12.
Related News:Taxotere® Effective in Early Breast Cancer (12/07/2006)
Copyright © 2018 CancerConnect. All Rights Reserved.